Search Tag: PAXLOVID

2024 09 Jun

  In a recent clinical trial, a 15-day course of nirmatrelvir-ritonavir targeting SARS-CoV-2 was found to be safe as an extended-duration treatment. However, it did not alleviate specific symptoms of long COVID. These findings are published in JAMA Internal Medicine.   The combination of nirmatrelvir-ritonavir is approved by the FDA for treating...Read more

2021 22 Dec

PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) is authorized for emergency use in both high-risk adults and high-risk pediatric patients 12 years of age and older weighing at least 40 kg EUA based on clinical data from EPIC-HR study, showing PAXLOVID reduced risk of hospitalization or death by 89% (within three days of symptom...Read more